Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies |
| |
| Authors: | Daniel M Hartung Dennis McCarty Rongwei Fu Katharina Wiest Mady Chalk David R Gastfriend |
| |
| Affiliation: | 1. Oregon State University/Oregon Health & Science University College of Pharmacy, 3303 SW Bond Avenue, CH12C, Portland OR 97239;2. Department of Public Health and Preventive Medicine, Oregon Health & Science University, CB669, 3181 SW Sam Jackson Park Road, Portland, OR 97239;3. CODA, 1027 E. Burnside St., Portland, OR 97214;4. Treatment Research Institute, Public Ledger Building, Philadelphia, PA 19106;5. Alkermes, Inc., 852 Winter Street, Waltham, MA 02451 |
| |
| Abstract: | Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6 months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone. |
| |
| Keywords: | Naltrexone Alcohol dependence Opioid dependence |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
